Show simple item record

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.

dc.contributor.authorPavel, M
dc.contributor.authorHörsch, D
dc.contributor.authorCaplin, M
dc.contributor.authorRamage, J
dc.contributor.authorSeufferlein, T
dc.contributor.authorValle, Juan W
dc.contributor.authorBanks, P
dc.contributor.authorLapuerta, P
dc.contributor.authorSands, A
dc.contributor.authorZambrowicz, B
dc.contributor.authorFleming, D
dc.contributor.authorWiedenmann, B
dc.date.accessioned2015-05-19T14:18:23Zen
dc.date.available2015-05-19T14:18:23Zen
dc.date.issued2015-04en
dc.identifier.citationTelotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. 2015, 100 (4):1511-9 J Clin Endocrinol Metaben
dc.identifier.issn1945-7197en
dc.identifier.pmid25636046en
dc.identifier.doi10.1210/jc.2014-2247en
dc.identifier.urihttp://hdl.handle.net/10541/554173en
dc.description.abstractCarcinoid syndrome (CS) is associated with elevated serotonin, diarrhea, flushing, and increased risk of valvular heart disease. Many patients respond to somatostatin analogs initially, but response diminishes in most patients. Additional options are needed.
dc.language.isoenen
dc.rightsArchived with thanks to The Journal of clinical endocrinology and metabolismen
dc.titleTelotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.en
dc.typeArticleen
dc.contributor.departmentCharité - Universitätsmedizin , Department of Gastroenterology and Hepatology, 13353 Berlin Germanyen
dc.identifier.journalThe Journal of Clinical Endocrinology and Metabolismen
html.description.abstractCarcinoid syndrome (CS) is associated with elevated serotonin, diarrhea, flushing, and increased risk of valvular heart disease. Many patients respond to somatostatin analogs initially, but response diminishes in most patients. Additional options are needed.


This item appears in the following Collection(s)

Show simple item record